Small-Cell Lung Cancer - Pipeline Review, H1 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Small-Cell Lung Cancer - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.
Small-Cell Lung Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 47, 33, 2, 36 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Small-Cell Lung Cancer - Overview Small-Cell Lung Cancer - Therapeutics Development Small-Cell Lung Cancer - Therapeutics Assessment Small-Cell Lung Cancer - Companies Involved in Therapeutics Development Small-Cell Lung Cancer - Drug Profiles Small-Cell Lung Cancer - Dormant Projects Small-Cell Lung Cancer - Discontinued Products Small-Cell Lung Cancer - Product Development Milestones Appendix
For more information about this report visit https://www.researchandmarkets.com/research/jwl8bq/smallcell_lung?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006758/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Lung Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/05/2018 05:26 PM/DISC: 06/05/2018 05:26 PM